Coral Laboratories Ltd
Coral Laboratories Ltd (CORALAB) last reported results for the quarter ended Jun 2026, with sales of ₹29.62 crore and net profit of ₹5.39 crore. The stock last traded at ₹579, a market capitalisation of ₹207 crore, on a P/E of 10.9. Over the past 52 weeks the stock has ranged between ₹360 and ₹679. Figures are as of 6 Oct 2026 and are not real time.
Coral Laboratories Ltd share price and key metrics
- Current price
- ₹579
- Market cap
- ₹207 cr
- Stock P/E
- 10.9
- Book value
- ₹585
- ROE
- 7.79%
- ROCE
- 11.0%
- Dividend yield
- 0.35%
- 52w high / low
- 679/360
Metrics as of 6 Oct 2026. Not real time.
Track Coral Laboratories Ltd
Cruxal reads every Coral Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Coral Laboratories Ltd growth and returns
- 10 Years
- 1%
- 5 Years
- -2%
- 3 Years
- 3%
- TTM
- -5%
- 10 Years
- 3%
- 5 Years
- 3%
- 3 Years
- 36%
- TTM
- 3%
- 10 Years
- 2%
- 5 Years
- 7%
- 3 Years
- 26%
- 1 Year
- 9%
- 10 Years
- 9%
- 5 Years
- 8%
- 3 Years
- 10%
- Last Year
- 8%
Coral Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹29.62 cr, up 57.4% from ₹18.82 cr a year earlier. Net profit was ₹5.39 cr, up 110.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 32.23 | 22.99 | 28.13 | 18.82 | 19.03 | 21.56 | 26.48 | 29.62 |
| Expenses | 25.72 | 16.67 | 25.44 | 16.64 | 14.09 | 19.67 | 20.28 | 24.13 |
| Operating profit | 6.51 | 6.32 | 2.69 | 2.18 | 4.94 | 1.89 | 6.2 | 5.49 |
| OPM % | 20.20% | 27.49% | 9.56% | 11.58% | 25.96% | 8.77% | 23.41% | 18.53% |
| Other income | 2.54 | 2.52 | 1.71 | 2.05 | 3.03 | 2.49 | 2.64 | 2.15 |
| Interest | 0.01 | 0.02 | 0.04 | 0.06 | 0.1 | 0 | 0.01 | 0.03 |
| Depreciation | 0.51 | 0.5 | 0.51 | 0.45 | 0.45 | 0.69 | 0.54 | 0.66 |
| Profit before tax | 8.53 | 8.32 | 3.85 | 3.72 | 7.42 | 3.69 | 8.29 | 6.95 |
| Tax % | 25.21% | 26.08% | 26.49% | 31.18% | 21.56% | 24.93% | 36.91% | 22.45% |
| Net profit | 6.38 | 6.14 | 2.83 | 2.56 | 5.82 | 2.78 | 5.22 | 5.39 |
| EPS (₹) | 17.86 | 17.19 | 7.92 | 7.17 | 16.29 | 7.78 | 14.61 | 15.09 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Coral Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 115 | 86 | 97 |
| Operating profit | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 | 15 | 19 |
| OPM % | 24% | 17% | 14% | 8% | 16% | 11% | 4.9% | 19% | 23% | 18% | 19% |
| Net profit | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 24 | 16 | 19 |
| EPS (₹) | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 67.63 | 45.85 | 53.77 |
TTM is the trailing twelve months to the most recent quarter.
Coral Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 198 | 206 |
| Borrowings | 2 | 2 | 1 | 6 | 6 | 6 | 0 | 0 | 4 | 4 |
| Other liabilities | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 25 | 27 |
| Total liabilities | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 241 |
| Fixed assets | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 | 44 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 |
| Investments | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 52 | 46 |
| Other assets | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 152 | 150 |
| Total assets | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 241 |
As reported by the company. Total assets equal total liabilities by construction.
Coral Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 11 | 13 | -1 | -4 | 1 | 6 | 13 | -5 | -1 | 16 |
| Cash from investing | -10 | -13 | 3 | -2 | -0 | -6 | -3 | 1 | -0 | -18 |
| Cash from financing | 0 | -3 | -1 | 4 | 0 | 0 | -6 | 0 | 3 | 0 |
| Net cash flow | 1 | -2 | 1 | -2 | 1 | 0 | 4 | -4 | 1 | -2 |
| Free cash flow | 9 | 9 | -4 | -5 | -0 | 1 | 11 | -6 | -4 | -5 |
| CFO / operating profit | 85% | 124% | 31% | -59% | 28% | 127% | 383% | -4% | 23% | 150% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Coral Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% | 17% | 11% |
| Debtor days | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 | 107 | 125 |
| Inventory days | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 | 68 | 211 |
| Days payable | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 | 46 | 103 |
| Cash conversion cycle | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 | 129 | 233 |
| Working capital days | 164 | 161 | 171 | 241 | 178 | 222 | 221 | 183 | 140 | 203 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Coral Laboratories Ltd shareholding pattern
Promoters held 71.51% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 28.50% | 28.49% | 28.49% | 28.50% | 28.49% | 28.48% | 28.49% | 28.49% |
| No. of shareholders | 3,949 | 4,054 | 4,105 | 4,213 | 4,286 | 4,208 | 4,084 | 3,873 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Coral Laboratories Ltd corporate filings
- Coral Laboratories Limited passes all AGM resolutions with high shareholder approval, including financial statements, dividend declaration, director re-appointments, and auditor remunerationAGM/EGMlow impact
Cruxal's analysis: Coral Laboratories Limited conducted its 44th AGM on September 29, 2026, with all six…
Read the full analysis - Coral Laboratories Limited concludes 44th Annual General Meeting; adopts FY2026 financials and declares dividendAGM/EGMlow impact
Cruxal's analysis: Coral Laboratories Limited has successfully concluded its 44th Annual General Meeting…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Coral Laboratories Ltd approves Cost Audit Report for FY 2025-26Board Meetinglow impact
Cruxal's analysis: Coral Laboratories Ltd has formally announced the consideration and approval of its Cost…
Read the full analysis - Coral Laboratories Limited schedules Board Meeting for September 25, 2026, to consider Cost Audit ReportBoard Meetinglow impact
Cruxal's analysis: Coral Laboratories Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis - Coral Laboratories Ltd publishes newspaper notice regarding dispatch of AGM/EGM noticeCompany Updatelow impact
Cruxal's analysis: Coral Laboratories Ltd has completed the mandatory newspaper publication regarding the…
Read the full analysis - Coral Laboratories Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Coral Laboratories has filed its Annual Report for the financial year 2025-26, fulfilling…
Read the full analysis - Coral Laboratories Limited Announces 44th AGM and Declares Final Dividend of INR 2 per Share for FY 2025-26AGM/EGMhigh impact
Cruxal's analysis: Coral Laboratories Limited has scheduled its 44th Annual General Meeting for September…
Read the full analysis - Coral Laboratories Ltd publishes mandatory newspaper notice for regulatory complianceCompany Updatelow impact
Cruxal's analysis: Coral Laboratories Ltd has released a copy of its newspaper publication as part of its…
Read the full analysis - Coral Laboratories Ltd announces book closure for AGMCorp. Actionlow impact
Cruxal's analysis: Coral Laboratories Ltd has issued a notice regarding the closure of its Register of…
Read the full analysis - Coral Laboratories Limited schedules 44th Annual General Meeting for September 29, 2026AGM/EGMlow impact
Cruxal's analysis: Coral Laboratories Limited has formally announced the convening of its 44th Annual…
Read the full analysis - Coral Laboratories Limited announces 44th AGM date and book closure for final dividendCorp. Actionlow impact
Cruxal's analysis: Coral Laboratories Limited has scheduled its 44th Annual General Meeting for September…
Read the full analysis - Coral Laboratories reports strong Q1 FY27 performance with 57.4% YoY revenue growth and 110.1% YoY profit surgeBoard Meetinghigh impact
Cruxal's analysis: Coral Laboratories Limited delivered robust financial results for the quarter ended June…
Read the full analysis - Coral Laboratories Ltd announces newspaper publication regarding transfer of shares to IEPFCompany Updatelow impact
Cruxal's analysis: Coral Laboratories Ltd has published a notice in newspapers concerning the mandatory…
Read the full analysis - Coral Laboratories Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Coral Laboratories Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.